Search

Displaying results 3991 - 4000 of 4188 in total
  1. Drug

    Cixutumumab

    go.drugbank.com/drugs/DB12250
    Investigational

    Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.

  2. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    As of May 2013 no new trials had been registered.

  3. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.

  4. Drug

    ACR-16

    go.drugbank.com/drugs/DB05371
    Investigational

    ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington

  5. Drug

    AG-858

    go.drugbank.com/drugs/DB05502
    Investigational

    Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.

  6. Drug

    Mericitabine

    go.drugbank.com/drugs/DB12045
    Investigational

    Mericitabine has been investigated for the treatment of Hepatitis C, Chronic. Mericitabine is a polymerase inhibitor being developed for the treatment of chronic hepatitis C.

  7. Drug

    Erythroxylum catuaba bark

    go.drugbank.com/drugs/DB14300
    Investigational

    [A215262] The infusion is thought to carry stimulant and aphrodisiac effects,[A215262] and catuaba made specifically with _Trichilia catigua_ has been investigated for use in depression.[A215267]

  8. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.

  9. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    In comparison to synthetic forms of surfacant, natural forms such as Beractant have been found to have a reduced incidence of pneumothorax and reduced mortality.

  10. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria.